Year: 2026
Type: article
Abstract: From the FDA New ADHD medication on the horizonO tsuka has announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for centanafadine, once-daily extended-release capsules, a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.The NDA submission is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations.
DOI: 10.1002/cpu.31040
Author: Alison Knopf
Language: English
Subfield: Cognitive Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7130686316
FWCI:
Cites:
Cited by:
Related to: